title: Expression of metallothionein in lung carcinoma: correlation with histological type and grade.
abstract: OBJECTIVE
  Over-expression of cellular metallothionein occurs frequently in human tumours but the underlying mechanism remains unknown. The aim of this study was to assess metallothionein expression in cases of lung carcinoma and to correlate it with histopathological parameters.
  
  
  RESULTS
  Tumour tissue samples from 89 patients with lung carcinoma were immunostained by the streptavidin-biotin-peroxidase technique, using a monoclonal antibody against both metallothionein-1 and -2 isoforms. Positive matallothionein immunostaining was prominent in 44 out of 89 (49%) and negative in 45 out of 89 (51%) cases of lung carcinoma examined. Metallothionein positivity was prominent in 32 out of 43 (74%) cases of squamous cell lung carcinoma, and in 12 out of 35 (34%) cases of adenocarcinoma, while it was negative in all 11 cases of small-cell lung carcinoma examined, presenting a statistically significant difference between the different histological types. The intensity of metallothionein staining revealed a statistically significant difference between the squamous cell and adenocarcinoma cases examined. The pattern and extent of metallothionein staining in tumour cells and the expression of metallothionein in stromal cells were not correlated with histopathological parameters (type and grade) in metallothionein-positive cases of lung carcinoma examined. No association was found between metallothionein expression and lymph node status in the examined cases of lung carcinoma.
  
  
  CONCLUSIONS
  Our findings indicate that expression of metallothionein was evident in squamous cell lung carcinoma and adenocarcinoma, but absent in small-cell lung carcinoma, supporting evidence for participation of this protein in the biological mechanisms underlying the carcinogenic evolution in the lung.
authors.affiliation: Department of Histology and Embryology, University of Athens, Medical School, Athens, Greece. theocharis@ath.forthnet.gr
authors.forename: S
authors.initials: S
authors.lastname: Theocharis
authors.forename: C
authors.initials: C
authors.lastname: Karkantaris
authors.forename: T
authors.initials: T
authors.lastname: Philipides
authors.forename: E
authors.initials: E
authors.lastname: Agapitos
authors.forename: A
authors.initials: A
authors.lastname: Gika
authors.forename: A
authors.initials: A
authors.lastname: Margeli
authors.forename: C
authors.initials: C
authors.lastname: Kittas
authors.forename: A
authors.initials: A
authors.lastname: Koutselinis
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018288:Carcinoma, Small Cell / Q000378:metabolism* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008668:Metallothionein / Q000378:metabolism*; D008875:Middle Aged
chemical_list: D008668:Metallothionein